ZIA BC 011803 (ZIA) | |||
---|---|---|---|
Title | Cancer immunotherapy | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Ruppin, Eytan | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $421,442 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Cancer (100.0%) |
Melanoma (25.0%) Nervous System (25.0%) Neuroblastoma (25.0%) |
||
Research Type | |||
Technology Development and/or Marker Discovery Systemic Therapies - Discovery and Development |
|||
Abstract | |||
From a translation perspective, together with our collaborators, we aim to predict and test novel drug targets and biomarkers to treat cancer more effectively. Ongoing collaborative studies focus on genome-wide identification of effective combinations involving checkpoint inhibitors (possibly with targeted therapies) and on the identification of new targets for CAR-T therapy. Since joining the CCR in spring of 2018, we have been establishing our laboratory and building on our network of collaborations to carry out this work. |